Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

35.99 -0.03 (-0.08%)
Streaming Delayed Price Updated: 10:53 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Immunocore Reveals First Data From HIV Infection Candidate Study ↗
 
Via Benzinga
News headline image
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers ↗
Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March. 
Via Investor's Business Daily
News headline image
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Analyst Ratings for Immunocore Hldgs ↗
 
Via Benzinga
Where Immunocore Hldgs Stands With Analysts ↗
 
Via Benzinga
7 Analysts Have This to Say About Immunocore Hldgs ↗
 
Via Benzinga
News headline image
Where Immunocore Hldgs Stands With Analysts ↗
Immunocore Hldgs (NASDAQ:IMCR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Immunocore Hldgs ↗
Analysts have provided the following ratings for Immunocore Hldgs (NASDAQ:IMCR) within the last quarter: 
Via Benzinga
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
3 Pharma Stocks That Will Mint Millionaires ↗
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. 
Via InvestorPlace
News headline image
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
5 Analysts Have This to Say About Immunocore Hldgs ↗
Within the last quarter, Immunocore Hldgs (NASDAQ:IMCR) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022 ↗
 
Via Benzinga
News headline image
Immunocore is awarded the Prix Galien France award for KIMMTRAK
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
From Immunocore Holdings Limited
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022 ↗
 
Via Benzinga
News headline image
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday ↗
 
Via Benzinga
News headline image
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. 
Via Benzinga
News headline image
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
News headline image
Immunocore to present at the Jefferies London Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Dow Climbs More Than 400 Points, S&P 500 Rises 1.5% ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Friday. 
Via Benzinga
News headline image
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday ↗
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.